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Severe mesenteric ischemia with  
multiple organ failure in a patient  
previously treated with a humanized 
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death receptor-1 (pembrolizumab),  
a case of pembrolizumab associated 
catastrophic antiphospholipid syndrome? 
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A Rutgers4 and M van Meurs1  
Abstract
Immune checkpoint inhibitors are used in the treatment of different types of tumors including melanoma and non-
small cell lung carcinoma. The use of these inhibitors is associated with a broad spectrum of immune-related adverse 
effects. Here we report a case of a patient admitted to the intensive care unit with multiple organ failure due to 
catastrophic antiphospholipid syndrome following treatment with pembrolizumab, an immune checkpoint inhibitor, 
because of metastatic melanoma. The presented patient had multiple organ failure of lung, gastro-intestinal, renal, and 
the liver. Vascular thrombosis was confirmed by both imaging (pulmonary embolism on computed tomography–thorax) 
and histopathological examination of the intestines. In combination with the presence of IgA anti-cardiolipin antibodies 
and initially IgM anti-cardiolipin antibodies, catastrophic antiphospholipid syndrome was suspected. Despite treatment 
with plasmapheresis and corticosteroids, the patient died due to multiple organ failure. Catastrophic antiphospholipid 
syndrome is difficult to recognize and has high mortality rates despite supportive treatment. In this case report, 
discussion is provided regarding the possible immunological mechanism behind catastrophic antiphospholipid syndrome 
during or after treatment with immune checkpoint inhibitors. It is important to realize that in modern intensive care 
unit, more patients with immune-related adverse effects of the treatment with immune checkpoint inhibitors will be 
admitted, because of an increase in the number of patients treated with these checkpoint inhibitors. When these 
patients are admitted on the intensive care unit, multi-disciplinary consultation is important because of the difficulty of 
early recognition and optimal treatment of these possible lethal side effects.
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Introduction
Immune checkpoint inhibitors are increasingly used in the 
treatment of different types of malignant tumors including 
patients with metastatic melanoma and non-small cell lung 
carcinoma. In contrast to classical cytotoxic chemotherapy, 
immune checkpoint inhibitors, among which pembrolizumab, 
enhance activation of immune cells toward cancer cells.
Besides long successful anti-tumor treatment results, the 
use of immune checkpoint inhibitors is associated with a 
plethora of immune-related adverse effects (irAEs). These 
irAEs are mainly described as pulmonary, skin, gastro-
intestinal, hepatic, and endocrine adverse effects in the lit-
erature.1 The hematologic irAEs can induce cytopenias 
(neutropenia, thrombopenia, pancytopenia) and autoim-
mune hemolytic anemia.2 Although hematologic irAEs are 
rare, the complications can be life-threatening and there-
fore they need early recognition and prompt interventions 
to prevent mortality.2–4
Here we report the case of a 74-year-old patient with 
advanced melanoma and pembrolizumab treatment. He was 
admitted to the intensive care unit (ICU) with multiple organ 
failure and the differential diagnosis of catastrophic antiphos-
pholipid syndrome (CAPS) following pembrolizumab treat-
ment of advanced melanoma was made. In this case report, 
we highlight some important aspects of this case for diagno-
sis and treatment of this catastrophic disease by multi-disci-
plinary ICU teams.
Case report
A 74-year-old male patient was diagnosed 3 years ago with 
a superficial spreading melanoma on his back. The tumor 
had a Breslow thickness of 4.0 mm and there were two pos-
itive sentinel nodes in both axilla. After surgical resection, 
there was progression of disease 1 year later with increased 
size of lymph nodes in both axilla and retroperitoneal. 
There was suspicion of a solitary lung metastasis in the left 
upper lobe. The patient was referred to our tertiary center 
for escalation of treatment. Molecular testing showed a 
NRAS tumor mutation but no BRAF tumor mutation. 
Immunotherapy with a humanized monoclonal antibody 
against programmed death receptor-1 (PD-1), that is, pem-
brolizumab, was started.
A few months later, good clinical response was observed 
as the lung metastasis and the lymph nodes regressed. After 
9 months of treatment with pembrolizumab, the patient 
developed urticaria and erythema, which were indicated as 
an adverse effect and successfully treated with hydroxyzine 
and a topical corticosteroid. The patient was operated on a 
presumed appendicitis in another hospital. One and a half 
years later, the patient developed adrenal insufficiency and 
oral hydrocortisone supplementation was started. A com-
puted tomography (CT) showed stable disease with disap-
pearance of the lung metastasis, therefore pembrolizumab 
treatment was continued. After a total of 27 treatments, the 
immune therapy with pembrolizumab was terminated. 
Shortly thereafter, the patient developed complaints of dysp-
nea and coughing. Electrocardiography and echocardiogra-
phy were normal; however, a CT-scan showed bilateral 
pleural effusion and mesenteric panniculitis. A diagnostic 
pleural puncture was performed showing exudate with reac-
tive cells; however, no malignant cells were observed. With 
the work diagnosis of pleural serositis due to immunother-
apy, treatment with prednisolone was initiated (60 mg per 
day). Because of persistent dyspnea, a pleural drainage 
(1800 mL) was performed 1 week later with good symptom 
relieving effects. Again, no malignant cells were observed in 
the pleural fluid.
Two weeks later, the patient presented at the emergency 
room with dyspnea, fever (38.5°C) and cold shivers. He also 
had complaints of red and tearing eyes. He was hypoxic and 
suppletion of oxygen was started. Blood laboratory values 
are presented in Table 1. Electrocardiography, chest X-ray, 
and microbiological diagnostics showed no abnormalities. 
A CT-thorax was performed, showing pulmonary emboli in 
the right lung and progression of the bilateral pleural fluid. 
There were no signs of pneumonitis. After another pleural 
drainage (1600 mL), the patient was admitted to the general 
ward with therapeutic anticoagulation by means of low-
molecular-weight heparin. During his stay in the ward, the 
fever persisted and the C-reactive protein was rising 
(102 mg/L), Table 1. Bacterial pneumonia was suspected, 
for which piperacillin/tazobactam was started and the pred-
nisolone dose was halved (30 mg per day). On the fourth day 
of hospital admission, clinical deterioration occurred char-
acterized by means of vomiting, severe diarrhea, oliguria, 
and blue discoloration of the fingers. Despite fluid resusci-
tation, no improvement was observed and with suspicion on 
intestinal ischemia or perforation, a CT-abdomen was per-
formed, showing intra-abdominal free fluid, no free air, a 
slightly distended transverse colon, and no occluded mesen-
teric arteries.
On the fifth day, the patient was in acute respiratory dis-
tress and therefore admitted to the ICU, where respiratory 
support with nasal positive airway pressure was initiated. 
Striking findings at physical examination at admittance were 
a convex, tense, and silent abdomen with diarrhea and poor 
peripheral circulation with extensive mottling of the legs up 
to the abdomen; a prolonged capillary refill time of more 
than 4 s; and severe discoloration (blue-purple) of the fingers 
on both hands. Laboratory findings are shown in Table 1. 
Blood and sputum cultures were taken, antibiotics were con-
tinued, and a multi-disciplinary consultation was arranged 
with the intensivist, oncologist, the rheumatology and clini-
cal immunology specialist, and gastroenterologist. This team 
had a high suspicion of an irAE.
Additional laboratory markers were investigated (includ-
ing antinuclear, anti-DNA, and antiphospholipid antibodies 
and complement C3 and C4). Because of abdominal pain, 
nausea, and vomiting with suspicion on clostridium, colitis 
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or intestinal ischemia additional fecal diagnostics were per-
formed. The fecal cultures were negative together with a 
negative clostridium difficile nucleic acid amplification test. 
Fecal calprotectin levels were increased (305 mg/kg), 
whereas fecal elastase levels were decreased (115 ug/g).
The patient underwent a colonoscopy, showing charac-
teristic ischemic colitis in most parts of the colon, whereas 
the rectum was partly saved. Biopsies were taken and 
shortly thereafter an explorative laparotomy was per-
formed. Due to extensive intestinal ischemia, 150 cm of 
ischemic small intestine combined with the sigmoid was 
resected. Bowel continuity was not restored and a second 
look laparotomy was scheduled. In the ICU, the patient was 
sedated, mechanical ventilated, and hemodynamically sup-
ported with noradrenaline. Anti-cardiolipin (aCL) antibod-
ies were detected, and together with the clinical picture of 
progressive multi-organ thrombosis raised the suspicion of 
CAPS as an irAE.
On the third day of ICU stay, the patient was clinically 
deteriorating with progressive respiratory failure, oliguria, 
and impairment of the peripheral circulation. Based on fro-
zen section analysis of the small intestine and sigmoid sur-
gical specimens with macroscopic signs of extensive 
ischemia (Figure 1(a) and (b)), no clear evidence for a 
vasculitis could be found. The laboratory diagnostics 
showed aCL antibodies; aCL IgM: 26 MPL/mL and aCL 
IgA: 60 APL/mL, raising the suspicion on a CAPS. Lupus 
anticoagulant (LAC), aCL IgG, and autoantibodies to 
B2-glycoprotein 1 were negative together with negative 
previous test results of antinuclear antibodies, antineutro-
phil cytoplasmic autoantibodies, and antibodies to double-
stranded DNA. Complement C3 and C4 levels were normal. 
All blood and sputum cultures taken during the hospital—
and ICU—stay were negative. Due to the rapid disease pro-
gression over the past 24 h, plasmapheresis was started and 
intravenous corticosteroids were continued. Overnight pro-
gression of disease was observed with multiple organ fail-
ure of the heart, the lungs, the kidney, and the liver and 
further purple discoloration of the fingers and toes.
Further workup of the resection specimens showed 
ischemic changes in the mucosa were in the submucosa and 
more extensive in the subserosa; fibrinoid necrosis was seen 
in the branches of the small and medium-sized arteries 
(Figure 1(a) and (b)).
A second look laparotomy was performed where exten-
sive, deep ischemia of the small and large intestine was 
found. In the light of severe mesenteric ischemia and multi-
ple organ failure, further care for recovery was deemed 













pH 7.51 7.46 7.52 7.45 7.39 7.38
pCO2 (kPa) 4.4 3.6 2.8 3.5 5.0 5.2
pO2 (kPa) 9.3 8.1 9.8 9.6 8.5 8.9
spO2 (%) 95% 92 96 95 91 92
HCO3 (mmol/L) 27 20 17 18 23 23
Lactate (mmol/L) 1.5 1.9 2.2 2.1 2.1 2.7
Glucose (mmol/L) 5.8 7.7 7.4 7.4 7.4 6.4
Sodium (mmol/L) 137 134 134 136 137 137
Potassium (mmol/L) 4.1 4.1 3.6 3.6 4.1 4.6
Chloride (mmol/L) 105 108 108 108 110 108
Hb (mmol/L) 9.9 10.9 11.0 10.6 8.8 7.5
Leucocytes (109/L) 13.9 13.2 19.2 20.0 18.9 18.7
Trombocytes (109/L) 235 266 269 254 220 182
CRP (mg/L) 21 102 62 223 84 111
Creatinine (umol/L) 88 123 127 122 127 218
Ureum (mmol/L) 5.7 8.1 7.9 9.4 11.9 18.5
Calcium (mmol/L) 2.25 2.08 2.16 2.04 1.91 2.07
LDH (u/L) 168 211 232 191 175 1376
ASAT (u/L) 18 21 20 18 14 1840
ALAT (u/L) 55 48 35 26 20 1007
AF (u/L) 76 89 77 63 42 42
y-GT (u/L) 123 149 123 96 58 29
Bilirubine (umol/L) 7 – 5 5 3 7
PT (s) – – 13.6 – 16.5
APTT (s) – – 39 38 – 36
Fribrinogeen (g/L) – – 6.7 – 2.9
ICU: intensive care unit.
4 SAGE Open Medical Case Reports
Figure 1. Multiple examples of the pathological examination of the patient. Macroscopic ischemic small intestine (a), and macroscopic 
ischemic sigmoid (b). Microscopic examination of subserosal artery branch with fibrinoid necrosis and nearly total obliteration of the 
lumen (arrow) (c), the same artery with the Verhoeff staining showing lamina elastica interna (arrow) (d). Microscopic examination of 
fibrinoid necrosis of another artery branch with cell dust in the artery wall, neutrophilic granulocyte infiltration, and clear narrowing 
of the lumen (e), and fibrin deposition (arrow) and damage of the artery wall (f). C5b-9 protein deposition in the wall of blood vessels 
in the submucosa and muscularis propria (arrows) (g) and subserosa (h) suggestive of an immune mediated etiology. Positive external 
control of C5b-9 staining in the blood vessels of a transplanted kidney with rejection (i, j).
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futile. The patient died shortly after cessation of supportive 
therapy and maximum palliative care.
During autopsy, there were no signs of malignancy nor 
enlarged lymph nodes. In the large vessels, there were no 
thrombi nor emboli. The small and large intestine showed 
signs of ischemia macroscopically. Microscopic examina-
tion of the sectioned intestines and one adrenal gland showed 
however small blood vessels with thrombi in different phases 
varying from only fibrinoid deposits on the endothelium 
(existence in days) to re-endothelization (existence in weeks) 
(Figure 1(c)–(j)).
In the appendectomy specimen from approximately 1 year 
earlier, there was chronic active, ulcerative inflammation 
within the peri-appendiceal fat tissue blood vessels with 
signs of vasculitis with infiltration of the vessel wall; at that 
time, this was probably associated with the degree of inflam-
mation. By revision, we consider this finding to be related 
with the more recent findings.
Blood samples that were taken before this hospital admis-
sion were post mortem analyzed for aCL antibodies, show-
ing a raised aCL IgM: 40 MPL/mL and negative aCL IgA 
antibodies, indicating that the patient was in the process of 
developing multiple autoantibodies against cardiolipins.
Discussion
(Catastrophic) antiphospholipid syndrome and 
immune checkpoint inhibitors
In this case report, we present a patient who developed mul-
tiple organ failure due to CAPS following treatment with 
pembrolizumab, a humanized monoclonal antibody against 
PD-1 for advanced melanoma for a longer period of time. 
Antiphospholipid syndrome (APS) is characterized by 
venous and/or arterial thrombosis and/or pregnancy-related 
morbidity, combined with the presence of antibodies against 
phospholipid binding proteins and/or LAC, see E-Table 1 in 
Supplemental Material for revised APS classification criteria.5 
APS is considered as a multifactorial condition that involves 
both the adaptive and the innate immune system.6 APS is a 
primary autoimmune disease but it can also be secondary to 
other autoimmune diseases such as systemic lupus erythem-
atodes.7 Besides pregnancy complications, venous, arterial, 
and/or small vessel thrombosis, other common disease-
related features observed in a cohort of 1000 patients with 
either primary or autoimmune disease-associated APS were 
thrombocytopenia (22%), livedo reticularis (20%), superfi-
cial thrombophlebitis (9%), and stroke (13%) or transient 
ischemic attack (7%).7 A small subset of patients with APS 
develop multiple organ failure due to multiple thromboem-
bolic occlusions with rapid onset, which is called cata-
strophic APS (CAPS). For the diagnosis of CAPS, the 
patient must have evidence of involvement of three or more 
organ systems simultaneously or in less than 1 week, con-
firmed with imaging or histopathology and antiphospholipid 
antibodies, E-Table 2 in Supplemental Material.6 Although 
CAPS patients represent less than 1% of all patients with 
APS, it is usually a life-threatening situation that requires 
treatment in the ICU.7 Management of a patient with CAPS 
is challenging because CAPS evolves quickly, is difficult to 
recognize, and has high mortality rates despite supportive 
treatment. The development of autoimmunity is prevented 
by central and peripheral mechanisms. Central tolerance is a 
process regulated in both the thymus and bone marrow pro-
cess where self-reactive T or B lymphocytes are removed. 
This process is not complete. In addition, several peripheral 
mechanisms act to prevent autoimmunity, including the pres-
ence of suppressive regulatory T cells. These cells negatively 
regulate existing B cell autoimmunity. When new drug thera-
pies like pembrolizumab intervenes with these negative reg-
ulators, autoimmunity can develop. Due to the scarcity and 
complexity of CAPS, it is unclear which immunosuppressive 
treatment is most beneficial for patients with CAPS in addi-
tion to anticoagulation therapy. High-dose steroids, plasma 
exchange, and/or intravenous immunoglobulin presumably 
counteract pathogenic autoantibodies. Many experienced 
clinicians will add cyclophosphamide or rituximab to this 
regimen depending on the presumed underlying disease.
Pembrolizumab is a humanized monoclonal antibody 
against PD-1. PD-1 has two main ligands: PD-L1 and PD-L2 
and both are expressed by various cells, tissues, and tumors 
(including melanoma). When tumor antigens bind to PD-1 
on T cells, the tumor inhibits T-cell function. Antibodies 
binding to PD-1 block the interaction with tumor PD-L1 and 
PD-L2, which result in an active T-cell response and reacti-
vating anti-tumor immunity.8 The use of checkpoint inhibi-
tors is associated with a wide range of irAEs that can affect 
every organ.1 PD-1 inhibitors are known to have a lower 
incidence of irAEs compared with cytotoxic T-lymphocyte-
associated antigen 4 inhibitors (such as ipilimumab espe-
cially as monotherapy). The most common irAE in patients 
treated with pembrolizumab is rash (40%) although diarrhea 
and/or colitis are also observed in patients treated with 
checkpoint inhibitors.1 A grade 3/4 colitis has been described 
after long-term PDL-1 treatment but is mostly seen with the 
use of CTLA-4i compared to PD-1 (7% vs 1.8%).1,9 Other 
related irAEs are hepatitis, pneumonitis, endocrinopathies, 
and hematological manifestations such as isolated neutrope-
nia, thrombocytopenia. and autoimmune hemolytic anemia. 
These side effects are extensively reviewed elsewhere.2,10,11 
In this case, we describe pembrolizumab related irAE char-
acterized by rash, serositis, conjunctivitis, adrenal insuffi-
ciency, and CAPS. To our knowledge, all of these side effects 
are widely known and reported in literature, except for 
CAPS. This is the first report of CAPS in a patient with 
checkpoint inhibition treatment. In a literature search, we 
found three case reports of APS and the use of checkpoint 
inhibitors.12–14 However, no cases are reported with cata-
strophic APS following the use of immune checkpoint inhib-
itors. This might be explained by the scarcity of CAPS in 
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general, the relatively recent introduction of monoclonal 
antibody against PD-1 in larger patient groups, or by the fact 
that it is very difficult to diagnose (C)APS properly in 
patients who already developed multiple organ failure.7 All 
patients must have evidence of involvement of three or more 
organ systems which develop in a short period of time, with 
imaging or histopathological confirmation and laboratory 
confirmation of antiphospholipid antibodies.15 The sensitiv-
ity of these criteria were reviewed in 220 patients who were 
included in the website-based international registry of 
patients with catastrophic APS (CAPS registry) at 1 October 
2003. In these 220 patients, that were not critically ill, 89 
patients (51%) could be classified as having “definite” and 
70 (40%) as having “probable” catastrophic APS.16
The differential diagnosis of CAPS is broad and includes 
many diseases. Clinical manifestations due to sepsis or 
acute thrombotic microangiopathy, sometimes at unusual 
sites, can be seen in more (catastrophic) thrombotic syn-
dromes such as hemolytic-uremic syndrome, thrombocyto-
penic purpura, disseminated intravascular coagulation, 
heparin-induced thrombocytopenia, Hemolysis Elevated 
Liver enzymes and Low Platelets syndrome, Trousseau syn-
drome, and scleroderma renal crisis.6,17 The diagnostic eval-
uation of patients presenting with multifocal progressive 
thrombotic events should include a thorough medical his-
tory, physical examination and additive laboratory tests. 
The initial laboratory findings are important to confirm the 
suspected diagnosis and to guide treatment. All patients 
should be evaluated with a complete blood count and blood 
film, comprehensive metabolic tests, and coagulation tests. 
Besides that, global testing for antiphospholipid antibodies 
should be performed.17 Imaging (e.g. echocardiography or 
CT) plays another important diagnostic role, identifying the 
distribution and overall burden of the thrombotic microan-
giopathy.17 Consultation of an expert ophthalmologist on 
retinal changes could be considered to study microangiopa-
thy in this vascular bed.
Treatment options for caps in mods
The treatment of APS must have three aims: treat any precipi-
tating factors (such as infections), prevent and treat ongoing 
thrombotic events, and probably suppress the cytokine 
storm.15 Treatment of CAPS is not standardized because of 
the lack of literature.15 The management of CAPS was 
updated by the recently published European League against 
Rheumatism Recommendations for the management of APS 
in adults.18 The most commonly used treatments are antico-
agulation, corticosteroids, plasma exchange, intravenous 
immunoglobulin, and/or cyclophosphamide. The study of 
Asherson in the 1990s showed a higher survival rate when a 
combination of anticoagulation corticosteroids and plasma 
exchange or intravenous immunoglobulin was used,19 but this 
was not confirmed by a second study of the same author.20 
Until now, treatment based upon consensus and is a combina-
tion of therapeutic anticoagulation, high-dose steroids, and 
intravenous immunoglobulin or plasma exchange.18 In the 
case of our patient, anticoagulation, high-dose corticoster-
oids, and plasma exchange were used. Due to the suspicion 
on a pleural serositis, our patient already used a high dose of 
prednisolone (30 mg/day) prior to hospital admission, which 
was switched to hydrocortisone (100 mg/day) during ICU 
stay. Therapeutic anticoagulation was started by low-molecu-
lar-weight heparin ad hospital admission and was continued. 
During ICU stay, we started with plasma exchange of which 
our patient only received one session due to the progressive 
multiple organ failure.
What to do if you admit a patient with 
complications of checkpoint inhibitors at the ICU?
What we have learned is that diagnosis and treatment of a 
patient with possible complications due to checkpoint 
inhibitors is only possible within a multi-disciplinary team. 
For intensivist, it is important to realize that in the ICU, 
more patients with irAEs of the treatments with checkpoint 
inhibitors will be admitted, because of an increase in the 
number of patients treated with checkpoint inhibitors due 
to expanded indications and better and longer cancer 
survival.3,4
Conclusion
In summary, we present a patient with multiple organ failure 
due to CAPS following treatment with a monoclonal anti-
body against PD-1 (pembrolizumab). In this case report, we 
highlight some important aspects of this case for diagnosis 
and treatment of this catastrophic disease by multi-discipli-
nary ICU teams.
Take home message
Immune-related adverse events are frequently observed 
in patients using PD-1 inhibitors and these adverse events 
will be more frequently observed in the ICU as well.
(C)APS can be a new immune-related adverse event in 
patients who are treated with PD-1 inhibitors; CAPS is 
hard to diagnose in the critically ill patients with multiple 
organ failure.
When (C)APS is suspected or diagnosed, care for these 
critically ill patients should be multi-disciplinary.
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